• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测 COVID-19 mRNA 加强针接种后出现中重度副作用的因素:比利时初级保健提供者的前瞻性队列研究。

Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium.

机构信息

Centre for General Practice, Department of Family Medicine & Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.

Global Health Institute, Department of Family Medicine & Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.

出版信息

BMC Infect Dis. 2024 Oct 10;24(1):1135. doi: 10.1186/s12879-024-09969-8.

DOI:10.1186/s12879-024-09969-8
PMID:39390398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11468363/
Abstract

BACKGROUND

COVID-19 vaccine effectiveness declines months after vaccination. Therefore, it is likely that during the next few years, people may be repeatedly offered a booster vaccine to enhance humoral immunity levels. A growing number of people are questioning whether the benefits of a booster vaccine outweigh the side-effects.

OBJECTIVE

This study aims (1) to identify the most frequently reported side-effects after different doses of COVID-19 mRNA vaccines, (2) and the longest lasting symptoms; and (3) to predict the likelihood of having moderate-to-severe side-effects after a booster COVID-19 mRNA vaccine given individual- and vaccine-specific characteristics.

DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of a prospective cohort study in primary health care providers (PHCPs) in Belgium conducted between December 2020 and December 2021, and in February-March 2023.

METHODS

In nine subsequent surveys over a period of 2 years vaccine dose-number and side-effects after COVID-19 vaccines were collected. A Generalized Estimation Equations approach on the data of the first and second booster dose was used to investigate the probability of having moderate-to-severe side-effects after mRNA booster vaccination. Predictive performance of a binary classifier was assessed by looking at discrimination (i.e., quantified in terms of the area under the receiver operating characteristic curve). The final prediction model was validated using data with regard to the third booster by assessing misclassification rate, sensitivity and specificity.

RESULTS

In total, 11% of the PHCPs had moderate-to-severe side-effects after their booster COVID-19 mRNA vaccine. The most common side-effects of COVID-19 mRNA doses included fatigue, local pain at the injection site, general pains, and headache. These side-effects typically lasted for a median of 1 to 2 days. The final model included five predictors: sex, alcohol consumption, history of moderate-to-severe side-effects after any previous dose, recent COVID-19 infection, and the booster dose-number (first, second). Having experienced moderate-to-severe side-effects after any previous dose was the strongest predictor of moderate-to-severe side-effects following an mRNA vaccine booster, with an odds ratio (OR) of 3.64 (95% CI: 2.80-4.75). The OR for female sex was 1.49 (95% CI: 1.21-1.84) implying that females have a higher odds of moderate-to-severe side-effects following booster vaccination. The differences in effect for booster dose-number, alcohol consumption and recent COVID-19 infection was not significant.

CONCLUSION AND RELEVANCE

COVID-19 mRNA booster vaccination implies a low prevalence of moderate-to-severe side-effects among PHCPs, with a short median duration of symptoms if any. The strongest predictors are a history of moderate-to-severe side-effects after any previous dose and being female. These reassuring findings can help addressing concerns about booster vaccination and encourage their uptake.

TRIAL REGISTRATION

NCT04779424 (registration date: 2021-02-22).

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d19/11468363/f71ae212cb3e/12879_2024_9969_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d19/11468363/978c16edcaf8/12879_2024_9969_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d19/11468363/f71ae212cb3e/12879_2024_9969_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d19/11468363/978c16edcaf8/12879_2024_9969_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d19/11468363/f71ae212cb3e/12879_2024_9969_Fig2_HTML.jpg
摘要

背景

接种 COVID-19 疫苗几个月后,疫苗的有效性会下降。因此,在未来几年,人们可能会反复接种加强针,以提高体液免疫水平。越来越多的人开始质疑加强针疫苗的益处是否超过其副作用。

目的

本研究旨在:(1)确定接种不同剂量的 COVID-19 mRNA 疫苗后最常报告的副作用;(2)以及最长持续时间的症状;(3)预测接种 COVID-19 mRNA 加强针后出现中重度副作用的可能性,根据个体和疫苗的特征。

设计、地点和参与者:这是一项在比利时基层医疗保健提供者(PHCPs)中进行的前瞻性队列研究的二次分析,该研究于 2020 年 12 月至 2021 年 12 月以及 2023 年 2 月至 3 月进行。

方法

在为期 2 年的 9 次后续调查中,收集了 COVID-19 疫苗接种剂量和副作用的数据。使用广义估计方程方法对第一针和第二针加强针的数据进行分析,以研究 mRNA 加强针接种后出现中重度副作用的可能性。通过观察接受者操作特征曲线下的面积来评估二分类器的预测性能。使用第三针加强针的数据来验证最终预测模型,通过评估误分类率、敏感性和特异性来验证模型的准确性。

结果

共有 11%的 PHCPs 在接种 COVID-19 mRNA 加强针后出现中重度副作用。COVID-19 mRNA 疫苗接种的最常见副作用包括疲劳、注射部位局部疼痛、全身疼痛和头痛。这些副作用通常持续 1 至 2 天。最终模型纳入了五个预测因素:性别、饮酒、以前任何剂量后出现中重度副作用的病史、近期 COVID-19 感染和加强针剂量数(第一针、第二针)。以前任何剂量后出现中重度副作用是接种 mRNA 加强针后出现中重度副作用的最强预测因素,比值比(OR)为 3.64(95%CI:2.80-4.75)。女性的 OR 为 1.49(95%CI:1.21-1.84),这意味着女性在接种加强针后出现中重度副作用的可能性更高。对于加强针剂量数、饮酒和近期 COVID-19 感染,其效应差异无统计学意义。

结论和相关性

COVID-19 mRNA 加强针接种在 PHCPs 中引起中重度副作用的患病率较低,如果出现任何症状,其症状的中位数持续时间较短。最强的预测因素是以前任何剂量后出现中重度副作用的病史和女性。这些令人安心的发现可以帮助解决对加强针接种的担忧,并鼓励其接种。

试验注册

NCT04779424(注册日期:2021-02-22)。

相似文献

1
Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium.预测 COVID-19 mRNA 加强针接种后出现中重度副作用的因素:比利时初级保健提供者的前瞻性队列研究。
BMC Infect Dis. 2024 Oct 10;24(1):1135. doi: 10.1186/s12879-024-09969-8.
2
What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.免疫功能低下患者接种 COVID-19 疫苗的安全性如何?来自欧洲“Covid 疫苗监测”主动监测研究的结果。
Drug Saf. 2024 Oct;47(10):1011-1023. doi: 10.1007/s40264-024-01449-x. Epub 2024 Jun 22.
3
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.接种加强针后感染 SARS-CoV-2:一项前瞻性、基于社区的病例对照研究中的疾病和症状特征。
J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28.
4
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.在 SARS-CoV-2 初免和既往感染人群中,BNT162b2 mRNA 疫苗对细胞和体液免疫应答的动力学和持久性:加强针和突破性感染的影响。
Front Immunol. 2022 May 31;13:863554. doi: 10.3389/fimmu.2022.863554. eCollection 2022.
5
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗(ARCT-154)与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性:一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
6
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
7
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
8
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.利用电子健康记录监测 3 剂 COVID-19 mRNA 疫苗接种的安全性。
JAMA Netw Open. 2022 Apr 1;5(4):e227038. doi: 10.1001/jamanetworkopen.2022.7038.
9
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.在比利时初级保健提供者中针对 SARS-CoV-2 的抗体的流行率、发生率和持久性:一项前瞻性队列研究,随访 12 个月。
BMJ Open. 2022 Sep 19;12(9):e065897. doi: 10.1136/bmjopen-2022-065897.
10
COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.COVID-19 疫苗接种和系统性硬化症患者的感染:硬皮病患者为中心干预网络(SPIN)队列研究。
Semin Arthritis Rheum. 2024 Aug;67:152453. doi: 10.1016/j.semarthrit.2024.152453. Epub 2024 May 9.

本文引用的文献

1
Primary Healthcare Providers' Views on Periodic COVID-19 Booster Vaccination for Themselves and Their Patients: A 2023 Nationwide Survey in Belgium.基层医疗服务提供者对自身及患者定期接种新冠病毒加强针的看法:2023年比利时全国性调查
Vaccines (Basel). 2024 Jul 3;12(7):740. doi: 10.3390/vaccines12070740.
2
Factors underlying COVID-19 booster vaccine uptake among adults in Belgium.比利时成年人接种 COVID-19 加强疫苗的因素。
BMC Res Notes. 2023 Nov 11;16(1):328. doi: 10.1186/s13104-023-06608-4.
3
Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece.
第一剂新冠病毒加强针后不良反应的患病率及风险因素:来自希腊的证据。
Vacunas. 2023 May 26. doi: 10.1016/j.vacun.2023.05.005.
4
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.含 Beta 二价新冠病毒加强疫苗对 COVID-19 的安全性、免疫原性和抗体持久性:一项 2/3 期试验。
Nat Med. 2022 Nov;28(11):2388-2397. doi: 10.1038/s41591-022-02031-7. Epub 2022 Oct 6.
5
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.美国 VISION 网络中成年人针对中度和重度 COVID-19 的疫苗有效性下降:阴性检测、病例对照研究。
BMJ. 2022 Oct 3;379:e072141. doi: 10.1136/bmj-2022-072141.
6
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.在比利时初级保健提供者中针对 SARS-CoV-2 的抗体的流行率、发生率和持久性:一项前瞻性队列研究,随访 12 个月。
BMJ Open. 2022 Sep 19;12(9):e065897. doi: 10.1136/bmjopen-2022-065897.
7
Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study.沙特阿拉伯东部省份医护人员中基于mRNA的新冠疫苗加强剂量相关副作用患病率评估:一项描述性横断面研究
Infect Drug Resist. 2022 Aug 9;15:4335-4346. doi: 10.2147/IDR.S374265. eCollection 2022.
8
COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study.波兰医护人员和学生对 COVID-19 疫苗加强针的犹豫(VBH):基于横断面调查的研究。
Front Public Health. 2022 Jul 25;10:938067. doi: 10.3389/fpubh.2022.938067. eCollection 2022.
9
A simple pooling method for variable selection in multiply imputed datasets outperformed complex methods.一种简单的池化方法在多重插补数据集的变量选择中表现优于复杂方法。
BMC Med Res Methodol. 2022 Aug 4;22(1):214. doi: 10.1186/s12874-022-01693-8.
10
Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose.新冠疫苗加强针自我报告的短期不良事件的风险因素及发生率
Vaccines (Basel). 2022 Jul 13;10(7):1115. doi: 10.3390/vaccines10071115.